IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS (2022) Siebert S, Coates L, Schett G, Raychaudhuri SP, Chen W, Gao S, Chakravarty SD, et al. Conference contribution RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CSDMARDS: DATA FROM THE ULTIMATE TRIAL (2022) D'Agostino MA, Boers M, Gaillez C, Gamez C, Ventura L, Padovano JRI, Mandl P, et al. Conference contribution "EFFECTIVE LUNG AGE" IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL (2022) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution DEVELOPING A SCREENING TOOL FOR THE DETECTION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS:THE ILD-RISC RISK SCORE (2022) Bruni C, Tofani L, Fretheim H, Liem S, Velauthapillai A, Bjorkekjaer J, Barua I, et al. Conference contribution THE FMF&AID SURVEY - A PATIENT ORGANIZATION DRIVEN SURVEY FOR AUTOINFLAMMATORY DISEASES (2022) Rech J, Tascilar K, Tufan A, Gattorno M, Kuemmerle-Deschner JB, Ozen S, Krickau T, et al. Conference contribution EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL (2022) Koehm M, Rossmanith T, Foldenauer AC, Kellner H, Kiltz U, Rech J, Burmester GR, et al. Conference contribution SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL (2022) Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Oommen P, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Conference contribution GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL (2022) Marzo-Ortega H, Theander E, Neuhold M, Bergmans P, Shawi M, Perate M, Contre C, et al. Conference contribution COMPARISON OF PATIENTS WITH AXIAL PSA AND PATIENTS WITH AXSPA AND CONCOMITANT PSORIASIS (2022) Regierer A, Weiss A, Baraliakos X, Behrens F, Poddubnyy D, Schett G, Lorenz HM, et al. Conference contribution